RE: RNS News17 Jan 2024 09:00
In the Finsmes coverage which DSFlatt shared last night, Staclica's plans for the $17.2 are set out. The last sentence is:
'Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2'. If you check Stalicla's site EVG's licensed partnership is referenced as STP2. So looks like something is happening. Bit nebulous at the moment. We were supposed to be starting the phase 2 trial for autism after data analysis on the phase 1b which was completed last August..
I think we need another RNS to clarify. Not sure that the one they have put out is any more helpful than the coverage of Stalicla's fundraise.